Monocyte-platelet aggregates

1. Empagliflozin decreases monocyte-platelet aggregates in humans (before-and-after comparison within participants, 12-week treatment) (-4.06% at 12 weeks; -2.88% at 2 weeks).

   “Empagliflozin significantly reduced MPAs at 2 weeks (-2.88% ± 2.11, p = 0.018) and 12 weeks (-4.06% ± 2.11, p = 0.002).”

   Human trialbefore-and-after comparison within participants, 12-week treatmentperipheral blood mononuclear cells25mg/day12 weeksfemalesn = 8

   SUN-559 Empagliflozin Reduces Monocyte-Platelet Aggregates: A Link to Cardiometabolic Benefits

   ENDO 2025 abstract·Oct 22, 2025

More on Empagliflozin

1. Beetroot decreases monocyte-platelet aggregates in humans.

   “Furthermore, the percentage of MPA significantly decreased (p < 0.05) at 3 h post-ingestion compared to baseline following ingestion of HI-NI beetroot juice ( C).”

   Human trialjuicen = 12

   Acute Effects of Nitrate-Rich Beetroot Juice on Blood Pressure, Hemostasis and Vascular Inflammation Markers in Healthy Older Adults: A Randomized, Placebo-Controlled Crossover Study

   Nutrients·Nov 22, 2017

More on Beetroot

1. Monocyte-platelet aggregates are linked with higher fatty acid β-oxidation in humans (compared with classical monocytes; PBMCs from healthy controls with SCENITH) (3.92% ±1.67 compared with classical monocytes).

   “Metabolic activity using the SCENITH protocol revealed increased fatty acid oxidation capacity in MPAs compared to classical monocytes (3.92% ±1.67, p= 0.002).”

   Humanscompared with classical monocytes; PBMCs from healthy controls with SCENITHperipheral blood mononuclear cells

   SUN-559 Empagliflozin Reduces Monocyte-Platelet Aggregates: A Link to Cardiometabolic Benefits

   ENDO 2025 abstract·Oct 22, 2025

More on Fatty acid β-oxidation